PanGenomic Health Announces Changes to Board of Directors and Management, Warrant Update and Stock Option Grants

(TheNewswire)

Vancouver, British Columbia, Canada,July 11, 2025 – TheNewswire - PanGenomic Health Inc.
("PanGenomic Health" or the "Company") NARA
is pleased to announce the appointment of Manpreet Dhillon as a
director of the Company. Ms. Dhillon has over 20 years of
international consulting experience specializing in implementing
programs on economic empowerment, gender equality, and stakeholder
engagement for international non-governmental organizations and
governments within the United Nations system. Ms. Dhillon is the
founder of Veza Global, a Canadian organization working globally to
provide solutions to support employers, human resource practitioners
and organizations as a whole to effectively address diversity, equity,
inclusion and belonging in the communities they serve. Ms. Dhillon has
significant experience as a strategic leader with expertise in equity,
diversity, and inclusion programs, strategic planning, stakeholder
engagement, brand development and leadership coaching. Ms. Dhillon
holds BBA and MA degrees.

The Company also announces the resignation of FranciscoKent Carasquero as a director and Chief Financial Officer of theCompany effective immediately. Current financial consultant TammyGillis has assumed the position of CFO, a role that she previouslyserved at the Company. Ms. Gillis is a CPA, CMA with over 20 years'experience in the public markets and brings a comprehensive backgroundin finance, reporting and regulatory requirements for juniorexploration, manufacturing, bio-technology, and technologyindustries.

The Company is also pleased to announce that it hasreceived approximately $731,000 in proceeds from the exercise of 4,300,464 share purchase warrants that were issued in May 2024 andrepriced to $0.17 per share as previously announced on January 29,2025. The proceeds will be used for general working capitalpurposes.

The Company also announces that its Board of Directorshas granted stock options representing a total of 1,350,000 commonshares to officers and directors of the Company.  These options weregranted at an exercise price of $1.15, being the closing price on July10, 2025, will vest in equal quarterly instalments over a one yearperiod, and will expire on July 11, 2028.  All options were grantedpursuant to the Company's Stock Option Plan.

About PanGenomic Health

PanGenomic Health is a precision health company thathas developed a self-care digital platform to deliver personalized,evidence-based information about natural treatments. The Company’sinitial focus is to support mental health. Registered as a BritishColumbia benefit company, PanGenomic Health's mission is to promoteand improve the health and wellness of people and society by providinga technology platform that identifies plant-based solutions tailoredto the health profile of each individual.

For more information, please contact:

• Jerry Lai, Investor Relations

  PanGenomic Health Inc.

  +1 778 743 4642

  ir@pangenomic.com

   

• Fairfax Partners Inc.

  Daniel Southan-Dwyer, President

  +1 604 366 6277

  connect@fairfaxpartners.ca

This news release includes certainstatements that may be deemed “forward-looking statements”,including statements respecting the services to be provided byPanGenomic Health and the consideration to be paid to PanGenomicHealth. The use of any of the words “anticipate”, “continue”,“estimate”, “expect”, “may”, “will”, “would”,“project”, “should”, “believe” and similar expressions areintended to identify forward looking statements. Although PanGenomicHealth believes that the expectations and assumptions on which theforward-looking statements are based are reasonable, undue relianceshould not be placed on the forward-looking statements becausePanGenomic Health can give no assurance that they will prove to becorrect. Since forward-looking statements address future events andconditions, by their very nature they involve inherent risks anduncertainties. These statements speak only as of the date of this NewsRelease. Actual results could differ materially from those currentlyanticipated due to a number of factors and risks including variousrisk factors discussed in PanGenomic Health’s disclosure documentswhich can be found under PanGenomic Health’s profile onwww.sedarplus.ca.

The Canadian Securities Exchange hasneither approved nor disapproved the information contained herein anddoes not accept responsibility for the adequacy or accuracy of thisnews release.

Copyright (c) 2025 TheNewswire - All rights reserved.